MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma

Mahdy, Hussein Ahmed El; Abdelhamid, Ismail A.; Amen, Ahmed Ibrahim; Abdelsameea, Eman; Hassouna, Mona Mahmoud

doi:10.31557/apjcp.2019.20.9.2723

Cited by 14 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 Hepatocellular carcinoma incidence is rising all over the world due to a rise in the incidence of HBV and HCV infection and increased prevalence of non-alcoholic fatty liver disease. 7 As classified by the WHO, the world can be divided into three types of area according to the prevalence of chronic HBsAg carriers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anti‐HBcand hepatitis B virusDNAamongHBsAg‐negative blood donors from the main central blood bank units in Eastern Libya

El-Nabi

El-Garawani

Ismail

et al. 2020

Transfusion Medicine

Self Cite

View full text Add to dashboard Cite

Background: Post-transfusion hepatitis B virus (PTHB) infection is still a public health problem in the world. In many developed countries, nucleic acid testing (NAT) for detection of Hepatitis B Virus (HBV)-DNA has been implemented to enhance blood donation safety. In Libya, however, the testing for HBV infection is limited to the detection of HBV surface antigen (HBsAg) only. Objectives: To determine the frequency of anti-Hepatitis B core antibody (HBc) and HBV-DNA in HBsAg-negative, anti-HBc-positive blood donors in the main Central Blood Bank Units (CBBUs) in eastern Libya. Methods: One thousand blood samples were obtained from healthy blood donors at the five main CBBUs in eastern Libya. The samples were screened for HBsAg and anti-HBc. Real-time polymerase chain reaction (PCR) was carried out to detect HBV-DNA in all anti-HBc-positive samples. Results: A total of 94 (9.4%) donors were positive for anti-HBc. Of the 94 anti-HBcpositive samples, 9 samples (9.5%) tested positive for HBV-DNA by real-time PCR. Conclusion: The rate of anti-HBc among blood donors in this study (9.4%) was similar to that reported from other regions in the country. In the absence of advanced tests for the detection of HBV infection in blood donors, such as NAT, anti-HBc should be routinely tested for, at least for first-time donors.

show abstract

Section: Introductionmentioning

confidence: 99%

“…In addition, treatments for chronic HBV infection have been updated and their efficiency improved 6 . Hepatocellular carcinoma incidence is rising all over the world due to a rise in the incidence of HBV and HCV infection and increased prevalence of non‐alcoholic fatty liver disease 7 …”

Section: Introductionmentioning

confidence: 99%

Anti‐HBcand hepatitis B virusDNAamongHBsAg‐negative blood donors from the main central blood bank units in Eastern Libya

El-Nabi

El-Garawani

Ismail

et al. 2020

Transfusion Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…And Shaker et al found the incidence of HCC in Egypt is overall increasing, from 4% in 1993 to 7.3% in 2003 [67]. Besides, the incidence rate of HCC among the cirrhosis patients in Egypt was approximately 21% [41], which might play an important role in the diagnosis of HCC. In addition, Yang, Y et al found the miRNAs had higher diagnostic efficacy in Asians with 22 DOR than Caucasians [72].…”

Section: Discussionmentioning

confidence: 99%

The Diagnostic Value of MicroRNAs as a Biomarker for Hepatocellular Carcinoma: A Meta-Analysis

Jiang

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Background Recently, the role of microRNAs (miRNAs) in diagnosing cancer has been attracted increasing attention. However, few miRNAs have been applied in clinical practice. The purpose of this study was to evaluate the diagnostic efficacy of miRNAs for hepatocellular carcinoma (HCC) at early stages clinically. Methods A literature search was carried out using PubMed, Web of Science, and EMBASE databases. We explored the diagnostic value of miRNAs in distinguishing HCC from healthy individuals. The quality assessment was performed in Review Manager 5.3 software. The overall sensitivity and specificity and 95% confidence intervals (CIs) were obtained with random-effects models through Stata 14.0 software. And heterogeneity was assessed using Q test and I2 statistics. Meta-regression and subgroup analyses were conducted based on the sample, nation, quality of studies, and miRNA profiling. The publication bias was evaluated through Deeks' funnel plot. Results A total of 34 studies, involving in 2747 HCC patients and 2053 healthy individuals, met the inclusion criteria in the 33 included literature studies. In the summary receiver operating characteristic (sROC) curve, AUC was 0.92 (95% CI, 0.90–0.94), with 0.84 (95% CI, 0.79–0.88) sensitivity and 0.87 (95% CI, 0.83–0.90) specificity. There was no publication bias (P=0.48). Conclusion miRNAs in vivo can be acted as a potential diagnostic biomarker for HCC, which can facilitate the early diagnosis of HCC in clinical practice.

show abstract

“… 1 , 2 As a malignant tumor disease, studies have shown that a variety of factors are involved in the complex development of liver cancer, 3 and its highly metastatic and invasive nature is a multistep process. 4 However, the cause of the disease is still unclear. Studies have shown that miRNAs have a variety of biological functions related to cancer progression, including cell survival, proliferation, and migration, and are closely related to the development of various tumors.…”

Section: Introductionmentioning

confidence: 99%

MiR-155 Inhibits Malignant Biological Behavior of Human Liver Cancer Cells by Regulating SRPK1

Wang

2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

Although the treatment of liver cancer has made great progress, the mechanism of its occurrence is not completely clear. miR-155 plays an important regulatory role in tumorigenesis and development, including survival, proliferation, migration and invasion. However, the role and regulatory mechanism of miR-155 in liver cancer has rarely been reported. We analyzed miR-155 expression in liver cancer tissue samples and cell lines by qRT-PCR. The expression of miR-155 was measured by qRT-PCR before and after miR-155-mimic and sh-miR-155 transfection. CCK-8 and clonogenic assays were used to detect the proliferation of liver cancer cells. Cell scratch and invasion assays were used to detect migration and invasion. RNA-seq was used to detect the difference in RNA expression in liver cancer cells. SRPK1 expression was detected in liver cancer cells before and after transfection by qRT-PCR and western blotting. We observed that miR-155 was downregulated in liver cancer tissues compared with normal tissues. Furthermore, we demonstrated that liver cancer cell proliferation, migration and invasion are markedly suppressed by miR-155. Importantly, we also demonstrated that SRPK1 is directly regulated by miR-155 during the process of liver cancer cell proliferation and metastasis. Finally, the overexpression of miR-155 inhibits malignant biological behavior of human liver cancer cells. We report the abnormal expression of the miR-155 cluster in liver cancer cells, which inhibits cancer cell proliferation and metastasis. In addition, we identified SRPK1 as a target gene of miR-155 during the process of liver cancer cell proliferation and metastasis.

show abstract

MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma

Cited by 14 publications

References 25 publications

Anti‐HBcand hepatitis B virusDNAamongHBsAg‐negative blood donors from the main central blood bank units in Eastern Libya

Anti‐HBcand hepatitis B virusDNAamongHBsAg‐negative blood donors from the main central blood bank units in Eastern Libya

The Diagnostic Value of MicroRNAs as a Biomarker for Hepatocellular Carcinoma: A Meta-Analysis

MiR-155 Inhibits Malignant Biological Behavior of Human Liver Cancer Cells by Regulating SRPK1

Contact Info

Product

Resources

About